Clinical Trial Update: A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for sotatercept in combined pre- and post-capillary pulmonary hypertension due to heart failure with preserved ejection fraction; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Pre- and Post-capillary Pulmonary Hypertension
• Heart Failure with Preserved Ejection Fraction
• Pulmonary Hypertension

Drugs mentioned

• Sotatercept (sotatercept)

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Hypertension, Pulmonary | Phase 2 | Status: COMPLETED